?Aris Global, a provider of software solutions for the life sciences industry, today announced the general release of agXchange IRT? (inbound receipt and triage) 6.0
Aris Global Expands Its Electronic Exchange Platform
with Release of agXchange IRT™ 6.0
Advanced software solution increases ability to report complete and accurate safety case information on time
AT THE DIA CONFERENCE (Boston, MA) - June 23, 2008: Aris Global, a leading provider of software solutions for the life sciences industry, today announced the general release of agXchange IRT™ (inbound receipt and triage) 6.0, a Web-based, solution for securely and efficiently receiving adverse event information, in different formats, from affiliates, co-development partners, consumers, healthcare providers, investigator sites, CROs, and other stakeholders.
During the DIA 44th Annual Meeting, Aris Global will be demonstrating and presenting agXchange IRT in its booth #834 in the Boston Convention and Exhibition Center.
agXchange IRT is the newest module of the agXchange™ gateway for extended electronic exchange, which also includes agXchange ESM™, an electronic submissions module that supports the import and export of adverse event data in E2B and extended E2B formats. agXchange IRT allows organizations to more closely integrate their affiliate offices into the processes of collecting and submitting safety information even if they do not have access to the central drug safety system. Comprehensive assessment and triage capabilities allow organizations to assess incoming potential safety items prior to case processing.
“Aris Global is committed to the extended electronic exchange gateway as the way organizations can take advantage of the inherent productivity benefits that automated paperless operations deliver,” said Wim Cypers, vice president, product management, Aris Global. “The agXchange IRT module will decrease the amount of time organizations spend collecting and verifying safety information, and will increase their ability to report complete and accurate safety information on time.”
About Aris Global
Aris Global (www.arisglobal.com) is a leading provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and medical information. More than 300 direct and indirect life science customers rely on the company’s advanced solutions for maintaining regulatory compliance, managing and mitigating risk, improving operational efficiency and easily sharing information on a global basis.
# # #
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.